Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the beta-exosite.

Article Details

Citation

Copy to clipboard

Smith GR, Caglic D, Capek P, Zhang Y, Godbole S, Reitz AB, Dickerson TJ

Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the beta-exosite.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3754-7. doi: 10.1016/j.bmcl.2012.04.019. Epub 2012 Apr 11.

PubMed ID

22542019 [ View in PubMed

]

Abstract

Botulinum neurotoxins (BoNTs) are the most toxic proteins known to man, exposure to which results in flaccid paralysis. Given their extreme potency, these proteins have become studied as possible weapons of bioterrorism; however, effective treatments that function after intoxication have not progressed to the clinic. Here, we have reexamined one of the most effective inhibitors, 2,4-dichlorocinnamyl hydroxamate, in the context of the known plasticity of the BoNT/A light chain metalloprotease. Our studies have shown that modifications of this compound are tolerated and result in improved inhibitors, with the best compound having an IC(50) of 0.23 muM. Given the inconsistency of structure-activity relationship trends observed across similar compounds, this data argues for caution in extrapolating across structural series.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE	Botulinum neurotoxin type A	IC 50 (nM)	670	N/A	N/A	Details